CN102216328A - 骆驼科动物来源的抗原结合多肽 - Google Patents

骆驼科动物来源的抗原结合多肽 Download PDF

Info

Publication number
CN102216328A
CN102216328A CN2009801343928A CN200980134392A CN102216328A CN 102216328 A CN102216328 A CN 102216328A CN 2009801343928 A CN2009801343928 A CN 2009801343928A CN 200980134392 A CN200980134392 A CN 200980134392A CN 102216328 A CN102216328 A CN 102216328A
Authority
CN
China
Prior art keywords
domain
antigen
binding polypeptide
encoding
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801343928A
Other languages
English (en)
Chinese (zh)
Inventor
托尔斯滕·德赖尔
克里斯托夫·弗雷德里克·杰罗姆·布朗什托·
约翰内斯·约斯夫·威廉默斯·德哈德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ArgenX SE
Original Assignee
ArgenX SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ArgenX SE filed Critical ArgenX SE
Priority to CN201710747051.4A priority Critical patent/CN107739405A/zh
Publication of CN102216328A publication Critical patent/CN102216328A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2009801343928A 2008-07-02 2009-07-02 骆驼科动物来源的抗原结合多肽 Pending CN102216328A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710747051.4A CN107739405A (zh) 2008-07-02 2009-07-02 骆驼科动物来源的抗原结合多肽

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US7773008P 2008-07-02 2008-07-02
GB0812120.4 2008-07-02
US61/077,730 2008-07-02
GB0812120A GB2461546B (en) 2008-07-02 2008-07-02 Antigen binding polypeptides
US11016108P 2008-10-31 2008-10-31
US61/110,161 2008-10-31
PCT/IB2009/006329 WO2010001251A2 (en) 2008-07-02 2009-07-02 Antigen binding polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710747051.4A Division CN107739405A (zh) 2008-07-02 2009-07-02 骆驼科动物来源的抗原结合多肽

Publications (1)

Publication Number Publication Date
CN102216328A true CN102216328A (zh) 2011-10-12

Family

ID=39707916

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2009801343928A Pending CN102216328A (zh) 2008-07-02 2009-07-02 骆驼科动物来源的抗原结合多肽
CN201710747051.4A Pending CN107739405A (zh) 2008-07-02 2009-07-02 骆驼科动物来源的抗原结合多肽

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710747051.4A Pending CN107739405A (zh) 2008-07-02 2009-07-02 骆驼科动物来源的抗原结合多肽

Country Status (8)

Country Link
EP (2) EP2310413B1 (https=)
JP (1) JP6216940B2 (https=)
CN (2) CN102216328A (https=)
AU (1) AU2009265278B2 (https=)
CA (1) CA2728076C (https=)
DK (1) DK2310413T3 (https=)
GB (1) GB2461546B (https=)
WO (1) WO2010001251A2 (https=)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102858800A (zh) * 2010-01-04 2013-01-02 阿尔金-X公司 人源化抗体
CN104520317A (zh) * 2012-07-20 2015-04-15 阿尔金-X公司 针对高度保守靶标的包含来自骆驼科之序列的抗体
CN104583236A (zh) * 2012-08-31 2015-04-29 阿尔金-X有限公司 高度多样的组合抗体文库
CN104583238A (zh) * 2012-08-31 2015-04-29 阿尔金-X有限公司 用于产生具有物种间、靶标内交叉反应性之抗体分子的方法
CN110139952A (zh) * 2016-12-09 2019-08-16 深圳华大生命科学研究院 骆驼科抗体可变区免疫组库构建的引物组合及应用
CN110642948A (zh) * 2019-10-09 2020-01-03 达石药业(广东)有限公司 B7-h3纳米抗体、其制备方法及用途
CN114126646A (zh) * 2019-02-27 2022-03-01 浙江纳米抗体技术中心有限公司 基于序列的高通量方法产生骆驼抗体以高分辨率覆盖广泛表位
CN116284375A (zh) * 2020-08-14 2023-06-23 上海洛启生物医药技术有限公司 非pH依赖性长效型抗血清白蛋白纳米抗体及其应用
CN119708213A (zh) * 2024-12-25 2025-03-28 河北科技师范学院 针对猪流行性腹泻病毒的纳米抗体或抗原结合片段及其应用

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
EP2576621B1 (en) 2010-05-27 2019-04-10 Genmab A/S Monoclonal antibodies against her2
DK2621531T3 (en) 2010-09-27 2017-02-27 Morphosys Ag ANTI-CD38 ANTIBODY AND LENALIDOMIDE OR BORTEZOMIB FOR TREATMENT OF MULTIPLE MYELOM AND NHL
RU2608644C2 (ru) 2010-11-03 2017-01-23 арДЖЕН-ИКС Н.В. Антитела против белка рецептора с-мет
AU2011352207B2 (en) * 2010-12-31 2016-03-03 Bioatla, Llc Comprehensive monoclonal antibody generation
EP2686347B1 (en) 2011-03-16 2018-05-02 argenx BVBA Antibodies to cd70
CN103796678B (zh) 2011-04-20 2018-02-27 健玛保 针对her2的双特异性抗体
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
EP4520771A3 (en) 2011-04-20 2025-07-16 Genmab A/S Bispecifc antibodies against her2
SG11201401422VA (en) 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
HK1220626A1 (zh) 2013-03-15 2017-05-12 The Centre For Drug Research And Development 具细胞毒性和抗有丝分裂的化合物以及其使用方法
ES2860952T3 (es) * 2013-08-01 2021-10-05 Univ Catholique Louvain Proteína anti-garp y usos de la misma
SG11201600853UA (en) 2013-08-05 2016-03-30 Twist Bioscience Corp De novo synthesized gene libraries
EP3066120B1 (en) 2013-11-04 2018-10-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Synthetic single domain antibody
WO2015095953A1 (en) 2013-12-27 2015-07-02 The Centre For Drug Research And Development Sulfonamide-containing linkage systems for drug conjugates
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
ES2905569T3 (es) 2014-09-17 2022-04-11 Zymeworks Inc Compuestos citotóxicos y antimitóticos y métodos para utilizarlos
RU2609627C2 (ru) 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
US10669304B2 (en) 2015-02-04 2020-06-02 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
EP3350314A4 (en) 2015-09-18 2019-02-06 Twist Bioscience Corporation OLIGONUCLEIC ACID VARIANT LIBRARIES VARIANT AND SYNTHESIS THEREOF
KR102794025B1 (ko) 2015-09-22 2025-04-09 트위스트 바이오사이언스 코포레이션 핵산 합성을 위한 가요성 기판
GB201611123D0 (en) 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
WO2018007999A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
US10417457B2 (en) 2016-09-21 2019-09-17 Twist Bioscience Corporation Nucleic acid based data storage
EP4556433A3 (en) 2017-02-22 2025-08-06 Twist Bioscience Corporation Nucleic acid based data storage
CN110506056A (zh) 2017-04-21 2019-11-26 斯塔滕生物技术有限公司 抗apoc3抗体和其使用方法
GB201707484D0 (en) 2017-05-10 2017-06-21 Argenx Bvba Method of preparing ph-dependent antibodies
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
WO2018231872A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
US11407837B2 (en) 2017-09-11 2022-08-09 Twist Bioscience Corporation GPCR binding proteins and synthesis thereof
CN111565834B (zh) 2017-10-20 2022-08-26 特韦斯特生物科学公司 用于多核苷酸合成的加热的纳米孔
PE20210119A1 (es) 2017-10-31 2021-01-19 Staten Biotechnology B V Anticuerpos anti-apoc3 y metodos de uso de estos
IT201800000535A1 (it) 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.
KR102804057B1 (ko) 2018-01-04 2025-05-07 트위스트 바이오사이언스 코포레이션 Dna 기반 디지털 정보 저장
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
GB201802487D0 (en) 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy
AU2019250689A1 (en) 2018-04-13 2020-10-08 Universiteit Gent Galectin-10 antibodies
CA3100739A1 (en) 2018-05-18 2019-11-21 Twist Bioscience Corporation Polynucleotides, reagents, and methods for nucleic acid hybridization
CN109206511B (zh) * 2018-09-13 2021-03-16 东南大学 能够特异结合HPVl6-E6蛋白的纳米抗体及其编码序列、制备方法和应用
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
WO2020139871A1 (en) 2018-12-26 2020-07-02 Twist Bioscience Corporation Highly accurate de novo polynucleotide synthesis
JP2022522668A (ja) 2019-02-26 2022-04-20 ツイスト バイオサイエンス コーポレーション 抗体を最適化するための変異体核酸ライブラリ
CN113766930B (zh) 2019-02-26 2025-07-22 特韦斯特生物科学公司 Glp1受体的变异核酸文库
WO2020178193A1 (en) 2019-03-01 2020-09-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment of sarcoidosis
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
US11332738B2 (en) 2019-06-21 2022-05-17 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
EP4034566A4 (en) 2019-09-23 2024-01-24 Twist Bioscience Corporation VARIANT NUCLEIC ACID BANKS FOR CRTH2
JP2022548783A (ja) 2019-09-23 2022-11-21 ツイスト バイオサイエンス コーポレーション 単一ドメイン抗体のバリアント核酸ライブラリー
BR112022011235A2 (pt) 2019-12-09 2022-12-13 Twist Bioscience Corp Bibliotecas de variantes de ácido nucleico para receptores de adenosina
CN114901817A (zh) * 2019-12-27 2022-08-12 株式会社钟化 引物组及使用其检测目标核酸的方法
GB202003444D0 (en) 2020-03-10 2020-04-22 argenx BV Musk agonist antibody
CN114591436B (zh) * 2020-12-07 2022-12-02 生物岛实验室 胃蛋白酶原i的特异性抗体及其制备方法与应用
WO2022263357A1 (en) 2021-06-14 2022-12-22 Argenx Iip Bv Anti-il-9 antibodies and methods of use thereof
CN118434440A (zh) 2022-01-18 2024-08-02 阿根思有限公司 Fab片段的雾化
IL314367A (en) 2022-01-18 2024-09-01 argenx BV Antibodies to galectin 10
GB202203269D0 (en) 2022-03-09 2022-04-20 Argenx Iip Bv TGF-Beta antibodies
JP2026507127A (ja) 2023-02-28 2026-02-27 ラノバ メディシンズ リミテッド Ｃｅａｃａｍ５依存性４－１ｂｂアゴニスト性二重特異性抗体
TW202504921A (zh) * 2023-02-28 2025-02-01 中國大陸商禮新醫藥科技（上海）有限公司 Ceacam5依賴性4-1bb促效性雙特異性抗體
CN117310163B (zh) * 2023-11-23 2024-02-13 北京贝思泰生物科技有限公司 一种基于重组抗体的呼吸道合胞病毒检测方法
CN117986360B (zh) * 2024-02-01 2024-08-27 生物岛实验室 Il18蛋白的特异性抗体及其制备方法与应用
CN119735700B (zh) * 2024-11-25 2025-09-23 江苏集萃崛创生物科技研究所有限公司 一种car-t细胞及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032714A1 (en) * 1999-11-03 2001-05-10 King's College London Recombinant fusion molecules
WO2005037989A2 (en) * 2001-01-17 2005-04-28 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2006122825A2 (en) * 2005-05-20 2006-11-23 Ablynx Nv Single domain vhh antibodies against von willebrand factor
WO2007136525A2 (en) * 2006-05-19 2007-11-29 Robert Webber Chimeric monoclonal antibody
WO2008070344A2 (en) * 2006-10-27 2008-06-12 Lpath, Inc. Compositions and methods for binding sphingosine-1-phosphate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1621554T4 (da) * 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US20050037420A1 (en) * 2001-09-14 2005-02-17 Mei-Yun Zhang Immunoglobulin having particular framework scaffold and methods of making and using
US8796429B2 (en) * 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
WO2008070367A2 (en) * 2006-11-01 2008-06-12 Facet Biotech Corporation Mammalian cell-based immunoglobulin display libraries
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032714A1 (en) * 1999-11-03 2001-05-10 King's College London Recombinant fusion molecules
WO2005037989A2 (en) * 2001-01-17 2005-04-28 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2006122825A2 (en) * 2005-05-20 2006-11-23 Ablynx Nv Single domain vhh antibodies against von willebrand factor
WO2007136525A2 (en) * 2006-05-19 2007-11-29 Robert Webber Chimeric monoclonal antibody
WO2008070344A2 (en) * 2006-10-27 2008-06-12 Lpath, Inc. Compositions and methods for binding sphingosine-1-phosphate

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHRISTELE MARTINEZ-JEAN AND JOUMANA JABADO-MICHALOUD: "Protein display: Arabian camel (Camelus dromedarius) IGH C-REGIONs", 《WWW.IMGT.ORG》 *
DOMINIQUE SCAVINER: "Protein display: Llama (Lama glama) IGH J-REGIONs", 《WWW.IMGT.ORG》 *
DOMINIQUE SCAVINER: "Protein display: Llama (Lama glama) IGH V-REGIONs", 《WWW.IMGT.ORG》 *
DOMINIQUE SCAVINER: "Table of alleles: Llama (Lama glama ) IGHV", 《WWW.IMGT.ORG》 *
IIHAM LEGSSYER: "The camel(camelus dromedarius) immunoglobulin light chains", 《THESIS; PROMOTERS: MULYDERMANS-S & HAMERS-R; ACADEMIC YEAR 2001-2002》 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102858800A (zh) * 2010-01-04 2013-01-02 阿尔金-X公司 人源化抗体
CN104520317A (zh) * 2012-07-20 2015-04-15 阿尔金-X公司 针对高度保守靶标的包含来自骆驼科之序列的抗体
CN104583236A (zh) * 2012-08-31 2015-04-29 阿尔金-X有限公司 高度多样的组合抗体文库
CN104583238A (zh) * 2012-08-31 2015-04-29 阿尔金-X有限公司 用于产生具有物种间、靶标内交叉反应性之抗体分子的方法
CN110139952A (zh) * 2016-12-09 2019-08-16 深圳华大生命科学研究院 骆驼科抗体可变区免疫组库构建的引物组合及应用
CN110139952B (zh) * 2016-12-09 2022-11-25 深圳华大生命科学研究院 骆驼科抗体可变区免疫组库构建的引物组合及应用
CN114126646A (zh) * 2019-02-27 2022-03-01 浙江纳米抗体技术中心有限公司 基于序列的高通量方法产生骆驼抗体以高分辨率覆盖广泛表位
CN110642948A (zh) * 2019-10-09 2020-01-03 达石药业(广东)有限公司 B7-h3纳米抗体、其制备方法及用途
CN116284375A (zh) * 2020-08-14 2023-06-23 上海洛启生物医药技术有限公司 非pH依赖性长效型抗血清白蛋白纳米抗体及其应用
CN119708213A (zh) * 2024-12-25 2025-03-28 河北科技师范学院 针对猪流行性腹泻病毒的纳米抗体或抗原结合片段及其应用
CN119708213B (zh) * 2024-12-25 2025-12-12 河北科技师范学院 针对猪流行性腹泻病毒的纳米抗体或抗原结合片段及其应用

Also Published As

Publication number Publication date
CA2728076A1 (en) 2010-01-07
AU2009265278A1 (en) 2010-01-07
GB2461546B (en) 2010-07-07
JP2011526493A (ja) 2011-10-13
JP6216940B2 (ja) 2017-10-25
DK2310413T3 (en) 2017-06-06
EP3061768A1 (en) 2016-08-31
EP2310413B1 (en) 2017-03-01
AU2009265278B2 (en) 2015-03-19
WO2010001251A3 (en) 2010-03-11
CA2728076C (en) 2020-05-19
CN107739405A (zh) 2018-02-27
GB2461546A (en) 2010-01-06
EP2310413A2 (en) 2011-04-20
GB0812120D0 (en) 2008-08-06
WO2010001251A2 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
EP2310413B1 (en) Camelid derived antigen binding polypeptides
US9315576B2 (en) Antigen binding polypeptides
JP6250284B2 (ja) ヒト化抗体
JP2015524404A (ja) 高度に保存された標的に対するラクダ科動物由来の配列を含む抗体
WO2023161448A1 (en) Human-like target-binding proteins
JP2018064561A (ja) ラクダ科動物由来の抗原結合ポリペプチド

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Holland Breda

Applicant after: ARGEN-X B.V.

Address before: Rotterdam

Applicant before: ARGEN-X B.V.

CB02 Change of applicant information

Address after: Holland Breda

Applicant after: ARGEN-X B.V.

Address before: Holland Breda

Applicant before: ARGEN-X B.V.

COR Change of bibliographic data
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Holland Breda

Applicant after: Alkings Co.

Address before: Holland Breda

Applicant before: ARGEN-X B.V.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20180115

Address after: Belgium zwijnaarde

Applicant after: ARGEN-X B.V.

Address before: Holland Breda

Applicant before: Alkings Co.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20111012